GoAI
Get started
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

TNYA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.6973

+$0.0068 · +0.98%

Aug 21, 4:00 PM ET

TNYA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

47

Neutral

Sentiment

39

Bearish

Risk resilience

15

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Faraz Ali
Listed since
Jul 30, 2021
Employees
70

Market position

Day range

Current $0.6973

52-week range

Current $0.6973

Open
$0.7018
Previous close
$0.6905
Volume
1.15M
0.37× average
Average volume
3.16M
Average daily volume
Market cap
151.31M USD
Beta
2.79
Market reference 1
50-day average
$0.7621
-8.50% below average
200-day average
$0.832
-16.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
19.12M USD
EV / EBITDA
-0.23×
Earnings yield
-83.24%
Free cash flow yield
-63.29%

Profitability & efficiency

Return on equity
-73.50%
Return on assets
-61.66%
Return on invested capital
-69.39%

Financial health

Current ratio
6.84×

Financial statements

Income trends

Operating income

−93.33M USD+19.51%

Net income

−90.6M USD+18.48%
Income trends across reported periods−66.87M USD−90.26M USD−113.65M USD−137.04M USDOperating income, FY2021: −72.81M USDOperating income, FY2022: −125.62M USDOperating income, FY2023: −131.19M USDOperating income, FY2024: −115.95M USDOperating income, FY2025: −93.33M USDNet income, FY2021: −72.72M USDNet income, FY2022: −123.67M USDNet income, FY2023: −124.08M USDNet income, FY2024: −111.13M USDNet income, FY2025: −90.6M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −72.81M USD. Operating income FY2022 −125.62M USD. Operating income FY2023 −131.19M USD. Operating income FY2024 −115.95M USD. Operating income FY2025 −93.33M USD. Net income FY2021 −72.72M USD. Net income FY2022 −123.67M USD. Net income FY2023 −124.08M USD. Net income FY2024 −111.13M USD. Net income FY2025 −90.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold8.44M USD8.47M USD8.69M USD8.71M USD4.03M USD
Gross profit−8.44M USD−8.47M USD−8.69M USD−8.71M USD−4.03M USD
Research and development68.61M USD86.74M USD98.04M USD94.54M USD54.39M USD
Selling, general, and administrative24.72M USD20.74M USD24.47M USD22.37M USD14.39M USD
Operating expenses84.9M USD107.48M USD122.51M USD116.91M USD68.78M USD
Interest income2.68M USD4.74M USD7.06M USD1.95M USD108K USD
Depreciation and amortization8.44M USD8.47M USD8.69M USD8.71M USD4.03M USD
Operating income−93.33M USD−115.95M USD−131.19M USD−125.62M USD−72.81M USD
Net income−90.6M USD−111.13M USD−124.08M USD−123.67M USD−72.72M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
-9.70%
11 comparable reports
Latest EPS result
-0.2
Estimate -0.07 · Miss by 192.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.06-0.16-0.25-0.35Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MetQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual -0.28, estimate -0.31, surprise +9.68%, Beat. Q2 2025, reported May 7, 2025: actual -0.24, estimate -0.18, surprise -33.33%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.14, estimate -0.2, surprise +30.00%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.12, estimate -0.15, surprise +20.00%, Beat. Q1 2026, reported Mar 11, 2026: actual -0.12, estimate -0.13, surprise +7.69%, Beat. Q2 2026, reported May 6, 2026: actual -0.09, estimate -0.09, surprise 0.00%, Met estimate. Q3 2026, reported Aug 5, 2026: actual -0.2, estimate -0.068, surprise -192.70%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates19.06M12.77M6.48M191.25KQ1 '24No estimateQ1 '26EstimateQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2024, reported Mar 18, 2024: actual 17.66M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 11, 2026: actual —, estimate 3M USD, surprise —, Comparison unavailable. Q2 2026, reported May 6, 2026: actual 225K USD, estimate 7.5M USD, surprise -97.00%, Miss. Q3 2026, reported Aug 5, 2026: actual 1.11M USD, estimate 10M USD, surprise -88.90%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 802.5K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.00

186.82% upside
Past 12 months12-month forecastHigh $2.00Average $2.00Low $2.00

Rating distribution

6 ratings
Strong buy00%
Buy6100%
Hold00%
Sell00%
Strong sell00%

TNYA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TNYA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.8M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.31M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.08M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
152.86K
Weight
0.01%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
88.85K
Weight
0.39%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
8.71K
Weight
0.01%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
5.17K
Weight
0.00%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%
Avantis Total Equity Markets ETF 1 logoAvantis Total Equity Markets ETF 1AVTM
Market value
2.54K
Weight
—
AUM
795.5M USD
Expense ratio
0.23%
Price / 1D
$55.32020.00%

Continue in GoAI

Research TNYA

research.disclaimer